Phase II study of oral topotecan plus bevacizumab (topo-bev) for second-line treatment of small cell lung cancer (SCLC)

被引：2
|
作者：
Waterhouse, D. M.
Morgan, S. K.
Spigel, D. R.
Shankar, S.
Dharan, B.
Foose, D. E.
Bhatt, K.
机构：
[1] Oncol Hematol Care Inc, Cincinnati, OH USA
[2] Florida Canc Specialists, Naples, FL USA
[3] Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA
[4] GlaxoSmithKline, Collegeville, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.7055
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7055
引用
收藏
页数：1
相关论文
共 50 条
  • [31] DOCETAXEL-CARBOPLATIN (DC) AS SECOND LINE TREATMENT IN PATIENTS WITH SMALL CELL LUNG CANCER (SCLC): A PHASE II STUDY
    Van Riel, Sunit
    Schramel, Franz M. N. H.
    Smit, Hans J. M.
    Van Walree, Nico C.
    Groen, Harry J. M.
    Schreurs, Ad J. M.
    Biesma, Bonne
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1231 - S1231
  • [32] Comparative efficacy and safety of anlotinib and topotecan as second-line treatment in small cell lung cancer: a retrospective cohort study
    Du, Yang
    Liu, Xiao-Yan
    Si, Xiao-Yan
    Zhang, Xiao-Tong
    Zhou, Jing-Ya
    Wang, Yi
    Chen, Min-Jiang
    Zhang, Li
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (07)
  • [33] Zweitlinientherapie des kleinzelligen Lungenkarzinoms (SCLC)Second-line therapy for small cell lung cancer (SCLC)
    F. Griesinger
    T. Overbeck
    N. Niederle
    Der Onkologe, 2005, 11 (7): : 730 - 740
  • [34] Phase II study of fenretinide in patients with small cell lung cancer (SCLC) with progression after first- or second-line chemotherapy.
    Schneider, BJ
    Worden, F
    Gadgeel, S
    Hodges, C
    Parchment, R
    Zwiebel, J
    Kraut, M
    Kalemkerian, G
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 690S - 690S
  • [35] ALIMTA® (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer:: a phase II study
    Smit, EF
    Mattson, K
    von Pawel, J
    Manegold, C
    Clarke, S
    Postmus, PE
    ANNALS OF ONCOLOGY, 2003, 14 (03) : 455 - 460
  • [36] Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer
    Kosmas, C
    Tsavaris, NB
    Malamos, NA
    Vadiaka, M
    Koufos, C
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (01) : 119 - 126
  • [37] Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer
    von Pawel, Joachim
    Jotte, Robert
    Spigel, David R.
    O'Brien, Mary E. R.
    Socinski, Mark A.
    Mezger, Joerg
    Steins, Martin
    Bosquee, Leon
    Bubis, Jeffrey
    Nackaerts, Kristiaan
    Trigo, Jose M.
    Clingan, Philip
    Schuette, Wolfgang
    Lorigan, Paul
    Reck, Martin
    Domine, Manuel
    Shepherd, Frances A.
    Li, Shaoyi
    Renschler, Markus F.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (35) : 4012 - U160
  • [38] Phase II Study of Picoplatin As Second-Line Therapy for Patients With Small-Cell Lung Cancer
    Eckardt, John R.
    Bentsion, Dimitri L.
    Lipatov, Oleg N.
    Polyakov, Igor S.
    MacKintosh, Frederick R.
    Karlin, David A.
    Baker, Gizelle S.
    Breitz, Hazel B.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (12) : 2046 - 2051
  • [39] A phase I study of weekly oral topotecan in patients (pts) with relapsed small cell lung cancer (SCLC)
    Kontopodis, E.
    Vamvakas, L.
    Kalbakis, K.
    Vardakis, N. K.
    Sfakiotaki, G.
    Georgoulias, V.
    Agelaki, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [40] Second-line treatment of small-cell lung cancer
    MacCallum C.
    Gillenwater H.H.
    Current Oncology Reports, 2006, 8 (4) : 258 - 264
12345